MDZ Mds

MDS Pharma Services Names New Site Director for Facility in Geneva Appointment Signals Renewed Focus on CNS Pharmacology Services MONTREAL, Feb. 13 /PRNewswire-FirstCall/ -- MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has promoted Claire Abadie, Ph.D., to site manager for its Geneva, Switzerland, facility that offers CNS (Central Nervous System) Pharmacology and in vitro Safety Pharmacology services. "Dr. Abadie's promotion is a key element of the company's renewed and expanded focus on providing CNS Pharmacology and in vitro Safety Assessment services," said Gilbert Godin, group vice president, Early Stage Development. "We are putting considerable resources behind our effort to further develop and promote our capabilities and services in these important areas of drug discovery." The company offers non-GLP assays on in vivo models of the following CNS diseases: stroke, epilepsy, Alzheimer's disease, Parkinson's disease, Amyotrophic LateralSclerosis disease (also known as Lou Gerhig's Disease), anxiety, depression and schizophrenia. In addition, it offers in vitro Safety Pharmacology services focused on electrophysiology, such as patch-clamp evaluation of hERG potassium-channels in CHO cells and Action Potential analysis on Purkinje fibers. Dr. Abadie has served as the head of Cardiovascular Pharmacology and Electrophysiology in Geneva since 1998, and as study director for MDS Pharma Services' hERG patch-clamp assay cells since 2001.She earned her doctorate in Physiology and Cardiovascular Pharmacology from the University of Burgundy, Dijon, France. MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, the company applies advanced scientific and technological expertise to each stage of the drug discovery and development process - early stage: lead optimization, pre-IND research, pharmaceutical and biopharmaceutical development, early clinical research (bioequivalence, phases I-IIa) and bioanalysis; and late stage: global clinical development (phases IIb-IV) and central lab. For more information, visit MDS Pharma Services' Web site at http://www.mdsps.com/ . MDS Pharma Services is part of MDS Inc. (NYSE:MDZ)(TSE:MDS) an international health and life sciences company. At MDS Inc., our 10,000 highly skilled people provide services, products and instruments enabling health sciences organizations to enhance the well being of people around the world. We focus on helping discover and test new drugs, assisting doctors to diagnose and treat patients and preventing the spread of disease. Find out more about MDS Inc. at http://www.mdsintl.com/ or by calling 1-888-MDS-7222, 24 hours a day. DATASOURCE: MDS Pharma Services CONTACT: Kevin Langin of MDS Pharma Services, +1-402-476-2811 Web site: http://www.mdsps.com/ http://www.mdsintl.com/

Copyright